SG11201808582RA - Pyrrolotriazine compounds as tam inhibitors - Google Patents

Pyrrolotriazine compounds as tam inhibitors

Info

Publication number
SG11201808582RA
SG11201808582RA SG11201808582RA SG11201808582RA SG11201808582RA SG 11201808582R A SG11201808582R A SG 11201808582RA SG 11201808582R A SG11201808582R A SG 11201808582RA SG 11201808582R A SG11201808582R A SG 11201808582RA SG 11201808582R A SG11201808582R A SG 11201808582RA
Authority
SG
Singapore
Prior art keywords
wilmington
delaware
cut
augustine
incyte corporation
Prior art date
Application number
SG11201808582RA
Other languages
English (en)
Inventor
Yun-Long Li
xiaozhao Wang
Joseph Barbosa
David M Burns
Hao Feng
Joseph Glenn
Chunhong He
Taisheng Huang
Song Mei
Jincong Zhuo
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of SG11201808582RA publication Critical patent/SG11201808582RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
SG11201808582RA 2016-03-28 2017-03-27 Pyrrolotriazine compounds as tam inhibitors SG11201808582RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662314066P 2016-03-28 2016-03-28
US201662362934P 2016-07-15 2016-07-15
US201662438750P 2016-12-23 2016-12-23
PCT/US2017/024270 WO2017172596A1 (en) 2016-03-28 2017-03-27 Pyrrolotriazine compounds as tam inhibitors

Publications (1)

Publication Number Publication Date
SG11201808582RA true SG11201808582RA (en) 2018-10-30

Family

ID=58489114

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202009423QA SG10202009423QA (en) 2016-03-28 2017-03-27 Pyrrolotriazine compounds as tam inhibitors
SG11201808582RA SG11201808582RA (en) 2016-03-28 2017-03-27 Pyrrolotriazine compounds as tam inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202009423QA SG10202009423QA (en) 2016-03-28 2017-03-27 Pyrrolotriazine compounds as tam inhibitors

Country Status (28)

Country Link
US (5) US9981975B2 (pt)
EP (2) EP3436461B1 (pt)
JP (3) JP7034084B2 (pt)
KR (3) KR20230111268A (pt)
CN (3) CN114456175A (pt)
AU (3) AU2017241524B2 (pt)
BR (1) BR112018069612A2 (pt)
CA (1) CA3019145A1 (pt)
CL (1) CL2018002759A1 (pt)
CO (1) CO2018011550A2 (pt)
CR (1) CR20180516A (pt)
DK (1) DK3436461T3 (pt)
EC (2) ECSP18081153A (pt)
FI (1) FI3436461T3 (pt)
HR (1) HRP20231614T1 (pt)
IL (2) IL293496B2 (pt)
LT (1) LT3436461T (pt)
MX (1) MX2018011792A (pt)
PE (1) PE20190175A1 (pt)
PH (1) PH12018502102A1 (pt)
PL (1) PL3436461T3 (pt)
PT (1) PT3436461T (pt)
RS (1) RS65129B1 (pt)
SG (2) SG10202009423QA (pt)
SI (1) SI3436461T1 (pt)
TW (2) TWI828027B (pt)
UA (1) UA123785C2 (pt)
WO (1) WO2017172596A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
KR20230111268A (ko) 2016-03-28 2023-07-25 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
JOP20190156B1 (ar) 2016-12-23 2023-09-17 Bayer Pharma AG أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1
EP3673907A4 (en) 2017-08-23 2020-08-19 ONO Pharmaceutical Co., Ltd. CANCER TREATMENT PHARMACEUTICAL INCLUDING AX1 INHIBITOR AS AN EFFECTIVE INGREDIENT
EP3988552A1 (en) * 2017-09-27 2022-04-27 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
US20210177828A1 (en) * 2018-01-17 2021-06-17 Nanjing Transthera Biosciences Co., Ltd. Tam family kinase /and csf1r kinase inhibitor and use thereof
EP3743430B1 (en) 2018-01-26 2023-08-02 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
CN110627796B (zh) * 2018-06-21 2022-07-12 北京越之康泰生物医药科技有限公司 含氮杂环类衍生物及其在医药上的应用
AR117600A1 (es) * 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
CN111689991B (zh) * 2019-03-13 2023-06-09 习峰 取代的杂芳基化合物及其组合物和用途
CN110156836A (zh) * 2019-06-10 2019-08-23 成家钢 一种环丙基羰基亚甲基三苯基磷的制备方法
EP4005637A4 (en) * 2019-07-29 2023-07-19 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
CN112409361B (zh) * 2019-08-23 2022-08-16 山东轩竹医药科技有限公司 Tam抑制剂及其用途
EP4029862A4 (en) * 2019-09-06 2023-10-04 Shanghai Institute of Materia Medica, Chinese Academy of Sciences CONNECTION WITH AXL AND C-MET KINASE INHIBITORY ACTIVITY, THEIR PREPARATION AND USE
CN113336758B (zh) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 化合物7-碘吡咯并[2，1-f][1，2，4]三嗪-4-胺的一种新合成方法
IL296065A (en) 2020-03-06 2022-10-01 Incyte Corp Combined treatment including axl/mer and pd-1/pd-l1 inhibitors
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
WO2021233236A1 (zh) * 2020-05-18 2021-11-25 北京范恩柯尔生物科技有限公司 取代的杂芳基化合物及其组合物和用途
CN113912628B (zh) * 2020-07-10 2023-05-02 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途
WO2022166610A1 (zh) * 2021-02-05 2022-08-11 四川科伦博泰生物医药股份有限公司 一类哒嗪酮杂环化合物及其制备方法和用途
WO2023016296A1 (zh) * 2021-08-12 2023-02-16 四川科伦博泰生物医药股份有限公司 一类杂环化合物及其制备方法和用途
TW202330519A (zh) * 2021-09-29 2023-08-01 香港商德琪研發有限公司 作為ｔａｍ抑制劑的吡唑并吡啶化合物
WO2023155886A1 (en) * 2022-02-17 2023-08-24 Shanghai Antengene Corporation Limited Pyrazolopyridine compounds as tam inhibitors
WO2024054793A1 (en) 2022-09-09 2024-03-14 University Of Rochester Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4908056A (en) 1986-04-25 1990-03-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
EP0352575A3 (de) 1988-07-28 1991-08-21 Bayer Ag Substituierte anellierte Pyrrole
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
IT1269176B (it) 1994-01-11 1997-03-21 Isagro Srl Eterobicicli ad attivita' fungicida
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
JP2001520268A (ja) 1997-10-14 2001-10-30 ザ、プロクター、エンド、ギャンブル、カンパニー 中鎖分枝鎖界面活性剤を包含する硬質表面クリーニング組成物
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
CN1390220A (zh) * 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的激酶抑制剂
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
CZ20013424A3 (cs) 1999-12-27 2002-02-13 Japan Tobacco Inc. Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva
CA2413330A1 (en) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
BR0208627A (pt) 2001-04-06 2004-03-09 Wyeth Corp Combinações antineoplásicas tal como rapamicina junto com gencitabina ou fluorouracila
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
AU2003272175A1 (en) 2002-10-21 2004-05-04 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
TW200505915A (en) 2003-03-13 2005-02-16 Synta Pharmaceuticals Corp Fused pyrrole compounds
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
WO2005003175A2 (en) 2003-06-13 2005-01-13 Biogen Idec Ma Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
FR2857966A1 (fr) 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
CA2536408A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20050203063A1 (en) 2003-09-12 2005-09-15 Raymond Deshaies Proteasome pathway inhibitors and related methods
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
AR053090A1 (es) * 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
CN101106983A (zh) 2004-11-24 2008-01-16 诺瓦提斯公司 JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2007056170A2 (en) 2005-11-02 2007-05-18 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
WO2007061737A2 (en) 2005-11-17 2007-05-31 Osi Pharmaceuticals, Inc. FUSED BICYCLIC mTOR INHIBITORS
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5193876B2 (ja) 2005-12-02 2013-05-08 バイエル・ヘルスケア・エルエルシー オーロラキナーゼの阻害により癌を処置するために有用なピロロトリアジン誘導体
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
MX2008007103A (es) 2005-12-02 2008-09-12 Bayer Healthcare Llc Derivados 4-amino-pirrolotriazina sustituidos, útiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis.
EP2348023B9 (en) 2005-12-13 2017-03-08 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US7601713B2 (en) 2005-12-15 2009-10-13 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
JP5512975B2 (ja) 2005-12-29 2014-06-04 アッヴィ・インコーポレイテッド タンパク質キナーゼ阻害薬
CA2649324A1 (en) 2006-04-12 2007-10-25 Jean-Damien Charrier Tetrahydropteridines useful as inhibitors of protein kinases
EA018917B1 (ru) 2006-04-19 2013-11-29 Новартис Аг 6-о-замещенные бензоксазолы и бензотиазолы и способы подавления передачи сигналов от csf-1r
EP2016077A2 (en) 2006-04-25 2009-01-21 Astex Therapeutics Limited Pharmaceutical compounds
EP2032560B1 (en) 2006-06-29 2013-05-01 Merck Sharp & Dohme Corp. Substituted bicyclic and tricyclic thrombin receptor antagonists
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
SI3034075T1 (sl) * 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
EP2428204A3 (en) 2006-12-07 2012-07-04 Schering Corporation pH sensitive matrix formulation
ES2359467T3 (es) 2006-12-14 2011-05-23 Vertex Pharmceuticals Incorporated Compuestos útiles como inhibidores de proteína quinasas.
PT2078010E (pt) 2006-12-29 2014-05-07 Rigel Pharmaceuticals Inc Triazoles substituídos com heteroarilos policíclicos úteis como inibidores de axl
US9650391B2 (en) 2006-12-29 2017-05-16 Rigel Pharmaceuticals Inc. N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors
WO2008083353A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2535345A1 (en) 2007-01-12 2012-12-19 BioCryst Pharmaceuticals, Inc. Anticancer nucleoside analogs
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
PL2155758T3 (pl) 2007-05-10 2013-06-28 Biocryst Pharm Inc Pochodne tetrahydrofuro[3,4-d]dioksolanu przeznaczone do stosowania w leczeniu infekcji wirusowych i raka
WO2009009016A1 (en) 2007-07-06 2009-01-15 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
JP2010532756A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
US8461149B2 (en) 2007-08-15 2013-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
CN101820762B (zh) 2007-09-25 2014-07-30 拜耳保健公司 透过抑制极光激酶而用于治疗癌症的吡咯并三嗪衍生物
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−０８３
SI2205592T1 (sl) 2007-10-26 2013-09-30 Rigel Pharmaceuticals, Inc. Triazoli substituirani s policikličnim arilom in triazoli substituirani s policikličnim heteroarilom uporabni kot Axl inhibitorji
DE102007051762A1 (de) 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
US8557814B2 (en) 2008-03-19 2013-10-15 OSI Pharmaceuticals, LLC mTOR inhibitor salt forms
US9206130B2 (en) 2008-04-16 2015-12-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline derivatives as AXL kinase inhibitors
AR071395A1 (es) 2008-04-23 2010-06-16 Gilead Sciences Inc Analogos carba-nucleosidos 1'-sustituidos para tratamiento antiviral
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
KR20110039278A (ko) 2008-06-23 2011-04-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제
KR20110018376A (ko) 2008-06-23 2011-02-23 스미또모 가가꾸 가부시키가이샤 조성물 및 상기 조성물을 이용하여 이루어지는 발광 소자
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
JP5592884B2 (ja) 2008-07-09 2014-09-17 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌ阻害剤として有用な多環式ヘテロアリール置換トリアゾール
EP2328888B1 (en) 2008-07-09 2012-11-07 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2010014755A1 (en) 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
US20100075973A1 (en) 2008-08-28 2010-03-25 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
JP2012506238A (ja) 2008-10-20 2012-03-15 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト インスリン様増殖因子−１受容体キナーゼ阻害剤に対する抗がん反応を予測する生物学的マーカー
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
EP2376491B1 (en) 2008-12-19 2015-03-04 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
EP2393814A1 (en) 2009-02-09 2011-12-14 SuperGen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
KR20100101054A (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
CN102458581B (zh) 2009-05-22 2016-03-30 因塞特控股公司 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2，3-d]嘧啶和吡咯-3-基-吡咯并[2，3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物
ME01838B (me) * 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
US20120128670A1 (en) 2009-07-31 2012-05-24 OSI Pharmaceuticals, LLC mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CR20190103A (es) 2009-09-21 2019-09-19 Gilead Sciences Inc ANÁLOGOS DE CARBA-NUCLEÓSIDOS SUSTITUIDOS CON 2'-FLUORO PARA TRATAMIENTO ANTIVIRAL (Divisional 2012-0186)
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
NZ599404A (en) 2009-09-21 2014-02-28 Gilead Sciences Inc Processes and intermediates for the preparation of 1’-substituted carba-nucleoside analogs
AU2010298190A1 (en) 2009-09-25 2012-05-03 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
CN102665718B (zh) 2009-10-06 2016-03-09 米伦纽姆医药公司 可用作pdk1抑制剂的杂环化合物
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
US8680108B2 (en) 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
ME02386B (me) 2010-03-10 2016-09-20 Incyte Holdings Corp Derivati piperidin-4-il azetidina kao inhibitori jak1
JP5752232B2 (ja) 2010-03-31 2015-07-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
JP2013525481A (ja) 2010-05-05 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド ＰＫＣ−θインヒビターとして有用な４置換ピラゾロピリミジン
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
GB2480814A (en) 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
JP5937073B2 (ja) 2010-07-19 2016-06-22 ギリード・サイエンシズ・インコーポレーテッド ジアステレオマーとして純粋なホスホルアミデートプロドラッグの調製方法
PE20171155A1 (es) 2010-07-22 2017-08-16 Gilead Sciences Inc Metodos y compuestos para tratar infecciones virales por paramyxoviridae
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
US9643969B2 (en) 2010-09-29 2017-05-09 Kissei Pharmaceutical Co., Ltd. (aza)indolizine derivative and pharmaceutical use thereof
AU2011313820A1 (en) 2010-10-08 2013-04-11 Biota Europe Ltd Antibacterial compounds
JP2013539759A (ja) 2010-10-08 2013-10-28 エラン ファーマシューティカルズ，インコーポレイテッド ポロ様キナーゼの阻害剤
ITRM20100537A1 (it) 2010-10-12 2012-04-12 Consiglio Nazionale Ricerche Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
EP2640723A1 (en) 2010-11-19 2013-09-25 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
AR085397A1 (es) 2011-02-23 2013-09-25 Intellikine Inc Combinacion de inhibidores de quinasa y sus usos
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
MY181439A (en) 2011-02-28 2020-12-22 Sunshine Lake Pharma Co Ltd Substituted quinoline compounds and methods of use
MY161199A (en) 2011-03-23 2017-04-14 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
EP2693881B1 (en) 2011-04-01 2019-09-04 University of Utah Research Foundation Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
ES2618489T3 (es) 2011-05-04 2017-06-21 Intellikine, Llc Composiciones farmacéuticas combinadas y usos de las mismas
WO2012154608A1 (en) 2011-05-06 2012-11-15 Intellikine, Llc Reactive mtor and pi3 kinase inhibitors and uses thereof
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
WO2012158764A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
KR102052670B1 (ko) 2011-05-17 2019-12-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키나아제 저해제
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
KR20140036269A (ko) 2011-07-01 2014-03-25 바이엘 인텔렉쳐 프로퍼티 게엠베하 Alk1 억제제로서의 히드록시메틸아릴-치환된 피롤로트리아진
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
MX2020004502A (es) 2011-09-02 2022-01-20 Incyte Holdings Corp Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k).
US9376395B2 (en) 2011-09-18 2016-06-28 Purdue Pharmaceuticals Products L.P. Pharmaceutical compositions
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
BR112014007788A2 (pt) 2011-10-03 2017-04-18 Univ North Carolina Chapel Hill compostos de pirrolopirimidina para tratamento do câncer
US20140377285A1 (en) 2011-11-08 2014-12-25 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
PL2780338T3 (pl) 2011-11-14 2017-04-28 Ignyta, Inc. Pochodne uracylu jako inhibitory kinaz AXL i c-MET
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
WO2013085802A1 (en) 2011-12-06 2013-06-13 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
EP2791143B1 (en) 2011-12-15 2016-02-24 Bayer Intellectual Property GmbH Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment of cancer
MX351812B (es) 2012-01-31 2017-10-27 Daiichi Sankyo Co Ltd Derivados de piridona.
WO2013113097A1 (en) 2012-01-31 2013-08-08 Beta Pharma Canada Inc. Cyclic molecules as bruton's tyrosine kinase inhibitors
US9475815B2 (en) 2012-02-23 2016-10-25 Bayer Intelletual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
WO2013162061A1 (ja) 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
DK2861599T3 (da) 2012-06-18 2020-03-02 Principia Biopharma Inc Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme
BR112014031798A2 (pt) 2012-06-19 2017-06-27 Sunovion Pharmaceuticals Inc compostos de heteroaril e métodos de uso destes
BR112014030147B1 (pt) 2012-06-22 2019-10-15 Sumitomo Chemical Company, Limited Compostos heterocíclicos fundidos, composição e método para controlar pestes
US9572811B2 (en) 2012-08-03 2017-02-21 Principia Biopharma Inc. Treatment of dry eye
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
CA2883894C (en) 2012-09-06 2020-08-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2014042433A2 (en) 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
RU2015115631A (ru) * 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модулирование ire1
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2909210A4 (en) 2012-10-17 2016-04-06 Merck Sharp & Dohme 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
EP2909209B1 (en) 2012-10-17 2022-08-03 Merck Sharp & Dohme LLC 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
PE20151141A1 (es) 2012-11-01 2015-08-06 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
EP2919785A4 (en) 2012-11-16 2016-10-05 Biocryst Pharm Inc ANTIVIRAL NUCLEOSIDES CONTAINING AZASUCRE
CN104936963B (zh) 2012-11-20 2017-11-28 普罗齐纳斯有限公司 作为蛋白激酶抑制剂的硫醚衍生物
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
JP6488239B2 (ja) 2013-01-18 2019-03-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としてのフタラジノンおよびイソキノリノン
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
US20140357636A1 (en) 2013-02-21 2014-12-04 Wayne Rothbaum Treatment of Skeletal-Related Disorders
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9012466B2 (en) 2013-03-12 2015-04-21 Arqule Inc. Substituted tricyclic pyrazolo-pyrimidine compounds
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
EP3057970A1 (en) 2013-10-18 2016-08-24 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
WO2015066371A1 (en) 2013-10-31 2015-05-07 Forum Pharmaceuticals, Inc. SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS
US9586967B2 (en) 2013-11-08 2017-03-07 Ono Pharmaceutical Co., Ltd. Pyrrolo pyrimidine derivative
MX2016009403A (es) * 2014-02-03 2016-09-16 Cadila Healthcare Ltd Compuestos heterociclicos.
CN106170488B (zh) 2014-02-12 2020-09-18 弗门尼舍公司 用于取代的1-苄基-3-(1-(异噁唑-4-基甲基)-1h-吡唑-4-基)咪唑烷-2,4-二酮的合成的改进方法
ES2746839T3 (es) 2014-12-18 2020-03-09 Pfizer Derivados de pirimidina y triazina y su uso como inhibidores de AXL
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
WO2017027717A1 (en) * 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
WO2017062797A1 (en) 2015-10-07 2017-04-13 The University Of North Carolina At Chapel Hill The methods for treatment of tumors
CA3000803C (en) 2015-10-13 2020-03-24 Nihon Nohyaku Co., Ltd. Oxime group-containing condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound, and method for using the insecticide
US9920033B2 (en) 2015-11-14 2018-03-20 Calitor Sciences, Llc Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
JP6905662B2 (ja) 2015-11-14 2021-07-21 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換キノリン化合物の結晶形およびその医薬組成物
KR20230111268A (ko) 2016-03-28 2023-07-25 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
PE20190377A1 (es) 2016-04-22 2019-03-08 Incyte Corp Formulaciones de un inhibidor de lsd 1
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
PL3484524T3 (pl) 2016-07-15 2023-03-20 Ionis Pharmaceuticals, Inc. Związki i sposoby modulacji smn2
EP3988552A1 (en) 2017-09-27 2022-04-27 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
IL296065A (en) 2020-03-06 2022-10-01 Incyte Corp Combined treatment including axl/mer and pd-1/pd-l1 inhibitors

Also Published As

Publication number Publication date
KR102558066B1 (ko) 2023-07-25
US9981975B2 (en) 2018-05-29
ECSP21008112A (es) 2021-07-30
IL293496A (en) 2022-08-01
TW201738246A (zh) 2017-11-01
US20170275290A1 (en) 2017-09-28
US20210147430A1 (en) 2021-05-20
CN114456175A (zh) 2022-05-10
TW202241903A (zh) 2022-11-01
PH12018502102A1 (en) 2019-07-29
AU2024201172A1 (en) 2024-03-14
SI3436461T1 (sl) 2024-03-29
AU2021245220A1 (en) 2021-11-04
CA3019145A1 (en) 2017-10-05
US10442810B2 (en) 2019-10-15
LT3436461T (lt) 2024-03-12
JP2023106404A (ja) 2023-08-01
IL293496B2 (en) 2023-05-01
JP2019510043A (ja) 2019-04-11
CO2018011550A2 (es) 2018-12-14
EP4321513A2 (en) 2024-02-14
PE20190175A1 (es) 2019-02-01
US20180327412A1 (en) 2018-11-15
US20240124463A1 (en) 2024-04-18
KR20230111268A (ko) 2023-07-25
EP3436461A1 (en) 2019-02-06
KR20230008241A (ko) 2023-01-13
AU2017241524A1 (en) 2018-11-15
TWI753892B (zh) 2022-02-01
EP3436461B1 (en) 2023-11-01
PT3436461T (pt) 2024-01-23
SG10202009423QA (en) 2020-11-27
RS65129B1 (sr) 2024-02-29
PL3436461T3 (pl) 2024-03-18
ECSP18081153A (es) 2019-02-28
IL293496B1 (en) 2023-01-01
MX2018011792A (es) 2019-07-04
JP7034084B2 (ja) 2022-03-11
IL261957A (en) 2018-10-31
CN114456176A (zh) 2022-05-10
CN109348715A (zh) 2019-02-15
AU2021245220B2 (en) 2023-11-23
WO2017172596A1 (en) 2017-10-05
FI3436461T3 (fi) 2024-01-16
KR20190013721A (ko) 2019-02-11
IL261957B (en) 2022-07-01
AU2017241524B2 (en) 2021-07-08
CN109348715B (zh) 2021-12-31
US10844069B2 (en) 2020-11-24
CL2018002759A1 (es) 2019-02-15
KR102483020B1 (ko) 2023-01-04
CR20180516A (es) 2019-03-05
HRP20231614T1 (hr) 2024-03-15
DK3436461T3 (da) 2024-01-02
BR112018069612A2 (pt) 2019-01-22
US20200131185A1 (en) 2020-04-30
TWI828027B (zh) 2024-01-01
US11591338B2 (en) 2023-02-28
JP2022084663A (ja) 2022-06-07
UA123785C2 (uk) 2021-06-02
JP7271750B2 (ja) 2023-05-11

Similar Documents

Publication Publication Date Title
SG11201808582RA (en) Pyrrolotriazine compounds as tam inhibitors
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201903487SA (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
SG11201809299QA (en) Formulations of an lsd1 inhibitor
SG11201806745RA (en) Sulfonylureas and related compounds and use of same
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201810579YA (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
SG11201804294WA (en) Tank-binding kinase inhibitor compounds
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201908640TA (en) Pyrrolidinones and a process to prepare them
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201909615YA (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201901995TA (en) Crystalline and salt forms of ppar agonist compounds
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201804587QA (en) Isoindole compounds